E1077 is a new iijectable cephalosporin with a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria, including staphylococci and Pseudomonas aeruginosa. The in vitro activities of E1077 against clinical isolates of methicillin-susceptible Staphylococcus aureus (MIC of E1077 for 90%o of the strains tested [MIC,0], 0.78 ;g/ml) and methicillin-resistant S. aureus (MIC90, 50 pLg/ml) were similar to those of cefpirome and flomoxef. Against Enterococcusfaecalis (MIC,0, 6.25 ;ag/ml), E1077 was the most active of the drugs tested and four times more active than cefpirome. The MIC90s of E1077 for streptococci, Haemophilus influenzae, and Neisseria gonorrhoeae ranged from 0.05 to 0.78 ,ug/ml; E1077 was similar in activity to cefpirome. E1077 inhibited 90% of most species of the family Enterobacteriaceae at concentrations of <1.56 iLg/ml, with the exception of Serratia marcescens and Proteus vulgaris (12.5 ,ug/ml). The activity of E1077 against P. aeruginosa (MIC90, 6.25 ;Lg/ml) was comparable to that of ceftazidime. In vivo activity was evaluated with systemic infections in mice. E1077 showed a protective effect against systemic infections by gram-positive or gram-negative bacteria, as reflected by its in vitro activity. The protective effects of E1077 were higher than those of cefpirome against S. aureus and P. aeruginosa infections and similar to those of cefpirome against other bacterial infections. Morphological studies using differential interference and phase-contrast microscopy showed that low concentrations of E1077 caused swelling of S. aureus and spheroplast and bulge formation in P. aeruginosa. In general, the antibacterial profile of E1077 is similar to that of cefpirome.
The newer cephalosporin antibiotics used in the treatment of bacterial infections, such as ceftazidime, cefuzonam, and flomoxef, possess broad antibacterial spectra. However, infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa still cause major clinical problems. Accordingly, there has been continued interest in producing cephalosporins with increased activity against MRSA or P. aeruginosa, such as cefpirome (12) , cefepime (5) , and E1040 (14) . E1077 {7,B-[2-(5-amino-1,2,4-thiadiazol-3-yl)-(Z)-2-fluoromethoxyiminoacetamido]-3 -[(E) -3 -(carbamoylmethyl) ethylmethylammonio -1 -propenyl] -3 -cephem -4 -carboxylate} is a new parenteral cephalosporin synthesized by Eisai Co., Ltd., Tokyo, Japan. It contains a unique side chain, a propenylammonium moiety at the 3 position, and a monofluoromethoxyimino group in the 71 side chain of the cephalosporin nucleus and has a broad antibacterial spectrum (4) . In this study, we compared the in vitro and in vivo antibacterial activities of E1077 with those of cefpirome (12) , ceftazidime (15) , cefuzonam (2) , cefotaxime (9) , and flomoxef (8) and examined the morphological changes in S. aureus and P. aeruginosa induced by E1077.
MATERIALS AND METHODS
Antibiotics. E1077 was provided by Eisai Co., Ltd. Cefpirome was provided by Hoechst Japan, Tokyo, Japan. The following other antibiotics were obtained commercially: ceftazidime (Tanabe Pharmaceutical Co., Osaka, Japan), Determination of MICs. MICs were determined by the agar dilution method recommended by the Japan Society of Chemotherapy (1) . Sensitivity test agar (Eiken) was used for all organisms except the following: streptococci (sensitivity test agar supplemented with 10% defibrinated horse blood), Haemophilus influenzae (sensitivity test agar supplemented with 5% Fildes enrichment), Branhamella catarrhalis (chocolate sensitivity test agar supplemented with 5% defibrinated horse blood), and Neisseria gonorrhoeae (chocolate sensitivity test agar supplemented with 10% defibrinated horse blood). Fresh cultures of the bacterial strains were diluted, and 5 pl of each bacterial suspension, corresponding to about 104 CFU, was spotted (Microplanter; Sakuma Seisakusho, Tokyo, Japan) onto agar plates that contained twofold serial dilutions of antibiotics. The MIC was the lowest concentration of an antibiotic that completely inhibited visible growth on agar plates after incubation for 18 h at 37°C. For N. gonorrhoeae, incubation was carried out in a candle jar. The MIC50 and MIC90 were the concentrations of a drug required to inhibit 50% and 90% of the strains, respectively.
Differential interference and phase-contrast microscopy. S. aureus Smith and P. aeruginosa E-2 were incubated in sensitivity test broth for 3 h at 37°C and then incubated on sensitivity test agar plates containing different concentra- Continued on following page tions of E1077. After 3 h of incubation, morphological changes of cells were examined by differential interference microscopy for S. aureus and by phase-contrast microscopy for P. aeruginosa. Systemic infection in mice. The protective effect of E1077 against systemic infections in mice was determined as described previously (3). Male ddY strain mice weighing 18 to 20 g were used. The bacterial strains, except for Streptococcuspneumoniae type III, were cultured overnight at 37°C in nutrient broth (Nissui). For S. pneumoniae, broth was supplemented with 10% horse serum. Challenge organisms were prepared in nutrient broth and 3% hog mucin (Orthana Kemisk Fabrik A/S) in sterile water. The mice were injected intraperitoneally with 0.5 ml of the bacterial suspension. The challenge inoculum was sufficient to kill 100% of untreated control mice within 48 h postinfection, with the exception of   FIG. 1 . Differential interference micrographs of S. aureus Smith exposed to E1077 for 3 h. Panels: A, untreated control; B, 0.025 ,ug/ml; C, 0.1 pLg/ml; D, 0.39 pg/ml; E, 1.56 .g/ml; F, 6 .25 ,g/ml.
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FIG. 2.
Phase-contrast micrographs of P. aeruginosa E-2 exposed to E1077 for 3 h. Panels: A, untreated control; B, 0.39 1Lg/ml; C, 1.56 ,ug/ml; D, 6.25 ,ug/ml; E, 25 ,ug/ml; F, 100 ,ug/ml. miCe infected with Klebsiella pneumoniae KC-1 or P. aeruginosa 15846, which died within 3 days after challenge. The antibiotic doses were administered subcutaneously in a volume of 0.2 ml of normal saline 2 h after infection. At least five levels (serial twofold doses) of the test compounds were employed with 10 mice at each level, and the 7-day survival ratios were determined. The 50% effective dose (ED50) was calculated by the Litchfield-Wilcoxon method (7) .
RESULTS
Antibacterial activity. The antibacterial activities of E1077, cefpirome, ceftazidime, cefuzonam, flomoxef, and cefotaxime against clinical isolates are shown in Table 1 . E1077 was active against staphylococci. The MIC90 of E1077 for methicillin-susceptible S. aureus strains was 0.78 ,ug/ml, which was similar to those of cefpirome, cefuzonam, and flomoxef and 1/16 to 1/4 times those of cefotaxime and ceftazidime.
The MIC50 and MIC90 of E1077 for MRSA strains were 6.25 and 50 ,ug/ml, respectively. Its MIC50 was similar to that of flomoxef and eight times lower than those of cefuzonam and cefpirome, and its MIC-w was similar to those of cefpirome, cefuzonam, and flomoxef. Ceftazidime and cefotaxime were inactive against MRSA, with MIC50s of >100 ,ug/ml. The activity of E1077 was comparable to that of cefpirome and cefuzonam against Staphylococcus epidermidis. Against streptococci, E1077 was comparable to cefpirome and cefotaxime and 4 to 16 times more active than ceftazidime and flomoxef. However, E1077 was four times less active than cefuzonam against S. pneumoniae. E1077, with an MIC90 of 6.25 ,ug/ml for Enterococcus faecalis, was the most potent of the compounds tested. It was four times more active than cefpirome. The other reference compounds did not inhibit most strains of E. faecalis at a concentration of 100 ,ug/ml or less. The MIC90s of E1077 for N. gonorrhoeae and H. influenzae were 0.05 and 0.20 ,ug/ml, respectively. E1077 was 4 to 16 times more active against these species than was flomoxef and was comparable to the other compounds tested. Against B.
catarrhalis, E1077, with an MIC90 of 0.78 ,ug/ml, was four times more active than cefpirome but eight times less active than ceftazidime.
In general, E1077 and cefpirome were more active against most members of the family Enterobacteriaceae than were the other compounds tested. The MIC90s of E1077 for Escherichia coli and K pneumoniae were 0.05 and 0.20 ,ug/ml, respectively. E1077 was equal to or four times more active than cefpirome against these species. The MIC90s of E1077 for Enterobacter cloacae, Enterobacter aerogenes, and Citrobacter freundii were 1.56, 0.20, and 0.78 jig/ml, respectively, and E1077 was equal to or four times more active than cefpirome and 64 to > 128 times more active than ceftazidime, cefuzonam, cefotaxime, and flomoxef against these species. Against Serratia marcescens, E1077 was comparable to cefpirome and eight or more times more active than the other reference compounds, with an MIC90 of 12.5 ,ug/ml. Against Morganella morganii and Providencia rettgeri, E1077 was equal to or 4 times more active than cefpirome and 4 to 64 times more active than ceftazidime and cefuzonam, with MIC90s of 0.39 and 0.39 ,g/ml, respectively. E1077 was similar in activity to cefpirome, ceftazidime, and cefotaxime and four times more active than cefuzonam against Proteus mirabilis. E1077 was four or more times less active than these reference compounds against Proteus vulgaris. Against P. aeruginosa, the activity of E1077 was similar to that of ceftazidime. The MIC50 and MIC90 of E1077 for P. aeruginosa were 1.56 and 6.25 ,ug/ml, respectively. The MIC50 of E1077 was equal to or four times lower than those of ceftazidime and cefpirome. E1077 was as active as cefpirome and ceftazidime against Acinetobacter calcoaceticus, with an MIC50 of 1.56 ,ug/ml and an MIC90 of 12.5 p,g/ml.
Morphological effects. The morphological changes induced by E1077 in S. aureus Smith and P. aeruginosa E-2 were examined by differential interference and phase-contrast microscopy, respectively. In S. aureus (Fig. 1) , E1077 induced a little swelling at a concentration of one-fourth of the MIC and lysis above the MIC. In P. aeruginosa (Fig. 2) , E1077 induced formation of filamentatous cells from normally rod-shaped cells at concentrations of one-fourth to four times the MIC. When P. aeruginosa cells were exposed to high concentrations of E1077 (25 and 100 ,ug/ml), formation of spheroplasts and bulges and cell lysis were observed.
Activity against systemic infections in mice. The in vivo activity of E1077 against systemic infections in mice is shown in Table 2 E1077 is a new injectable cephalosporin, which has been described by Watanabe et al. (13) , with a broad antibacterial spectrum and potent antibacterial activity. One of the antibacterial characteristics of E1077 is its activity against S. aureus and E. faecalis. The activity of E1077 against methicillin-susceptible S. aureus was comparable to those of cefpirome, cefuzonam, and flomoxef. E1077 also inhibited 50% and 90% of MRSA strains at concentrations of 6.25 and 50 ,ug/ml, respectively. Its activity was similar to that of flomoxef, which has been reported to be more active in vitro than other cephalosporins against MRSA (8) . However, its activity, with an MIC90 of 50 ,ug/ml, is probably inadequate for clinical use for MRSA infections. In addition, E1077 was active against E. faecalis, which was resistant or less susceptible to most of the existing cephalosporins. The MIC90 of E1077 for E. faecalis was 6.25 ,ug/ml, and its activity was four times that of cefpirome. The other reference compounds were inactive (MIC50s, >100 ,ug/ml). Kamiya et al. have suggested that the high activity of E1077 against S. aureus and E. faecalis is provided by the introduction of a quatemary ammoniopropenyl substituent at the 3 position of the cephem nucleus (4).
A second characteristic of E1077 is that E1077 is very effective against most members of the family Enterobacteriaceae. In general, the activity of E1077 was comparable to that of cefpirome and higher than those of the other reference compounds against these species. In particular, the activity of E1077 was much higher (.64 times) than those of ceftazidime, cefuzonam, cefotaxime, and flomoxef against Enterobacter and Citrobacter species, which produce high levels of chromosomal ,-lactamase (11). Cefpirome (6) and cefepime (10) have been reported to be active against these species. In this study, E1077 was four times more active than cefpirome against E. aerogenes and C. freundii. E1077 also showed higher in vivo activity against systemic infection caused by a strain of C. freundii that was resistant to the other extended-spectrum cephalosporins than did ceftazidime and cefuzonam. This activity seems to be due to the resistance of E1077 to enzymatic hydrolysis and the low affinity of the compound for 1-lactamases (13) .
E1077 possessed potency comparable to that of ceftazidime against P. aeruginosa, an opportunistic pathogen that is one of the major causes of life-threatening nosocomial bacterial infections. The M'C50 and MIC90 of E1077 for P. aeruginosa were 1.56 and 6.25 ,ug/ml, respectively, and its activity was comparable to that of ceftazidime and four times higher than that of cefpirome. Watanabe et al. have reported that introduction of the aminothiadiazolyl group in the 71 side chain of the cephem nucleus enhances antibacterial activity against P. aeruginosa (14) . The in vivo activity of E1077 in systemic infection clearly reflected its in vitro activity against P. aeruginosa.
Thus, E1077 has a broad antibacterial spectrum covering gram-positive bacteria, including staphylococci and E. faecalis, and gram-negative bacteria, including P. aeruginosa. The in vitro study results were generally consistent with those of Watanabe et al. (13) . E1077 also showed efficacy in systemic infections with various bacteria, and this was clearly reflected by its in vitro activity. Overall, E1077 is a very promising antibacterial agent for the treatment of various bacterial infections. Further studies on pharmacokinetic and toxicological behaviors are therefore warranted.
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